NASDAQ:CNCE

Concert Pharmaceuticals (CNCE) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$8.37
$8.37
50-Day Range
$8.33
$8.40
52-Week Range
$2.66
$8.55
Volume
N/A
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
CNCE stock logo

About Concert Pharmaceuticals Stock (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

CNCE Stock News Headlines

READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Profitability

Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

CNCE Stock Analysis - Frequently Asked Questions

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) released its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to the consensus estimate of $0.25 million. During the same period in the prior year, the company earned ($0.60) earnings per share.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?
This page (NASDAQ:CNCE) was last updated on 5/10/2024 by MarketBeat.com Staff

From Our Partners